00:16 , Aug 17, 2019 |  BC Extra  |  Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

SpringWorks, Satsuma, Monopar propose IPOs  SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and Monopar Therapeutics Inc. (Northbrook, Ill.) are looking to go public on NASDAQ. SpringWorks proposed to raise up...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
01:50 , Jun 7, 2019 |  BC Innovations  |  Translation in Brief

Binding the extracellular matrix to target brain tissue

Attaching biologics to an antigen receptor derived from a fish that preferentially binds the brain's extracellular matrix could enable targeted drug delivery to the CNS. A University of Wisconsin-Madison team found that lamprey-derived immune molecules...
00:10 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Targeting brain extracellular matrix to improve doxorubicin efficacy in GBM

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest doxorubicin-loaded nanoparticles targeted to brain extracellular matrix (ECM) could help treat glioblastoma multiforme (GBM). The nanoparticles consist of doxorubicin-loaded liposomes chemically linked to...
22:37 , May 29, 2019 |  BC Extra  |  Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
16:49 , Apr 25, 2019 |  BC Extra  |  Company News

Lilly pulling Lartruvo after failure in confirmatory study

Following the failure in January of Lartruvo olaratumab to show a survival benefit in a confirmatory study, Lilly now intends to withdraw the drug from the market. Since 2016, Lartruvo has been approved to treat...
17:29 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
21:44 , Apr 2, 2019 |  BC Innovations  |  Distillery Techniques

Dual-targeting liposomes for cancer therapy delivery

TECHNIQUES CATEGORY: Drug delivery TECHNOLOGY: Nanoparticles Dual-targeting liposomes could be used to deliver cancer therapies. Generation of the liposomes involves two steps: screening human cancer cell lines against a 68-gene panel of common cancer targets...
22:18 , Mar 13, 2019 |  BC Extra  |  Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

China's National Medical Insurance Administration released its plan for issuing a revised National Drug Reimbursement List Wednesday, describing which types of drugs will have priority for inclusion and sketching out a timeline for a revision...
21:15 , Mar 5, 2019 |  BC Innovations  |  Distillery Techniques

Vascularized kidney organoids for modeling renal disease

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: 3-D models Vascularized kidney organoids could be used to study kidney development and model renal diseases. The organoids are generated in three steps: culturing human pluripotent stem cells with fibroblast...